Molecular Subgroup Findings of IMmotion151 in RCC
Brian Rini, MD, professor of medicine, Cleveland Clinic, discusses subgroup findings from the IMmotion151 trial in metastatic renal cell carcinoma.
Brian Rini, MD, professor of medicine, Cleveland Clinic, discusses subgroup findings from the IMmotion151 trial in metastatic renal cell carcinoma (mRCC).
IMmotion151 evaluated the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) compared with sunitinib (Sutent) in patients with mRCC. In an effort to differentiate response by subgroup, Rini says that findings varied according to molecular profile and risk factor.
In the T effectorhigh subgroup, patients did better with the combination of atezolizumab plus bevacizumab. Rini says that is not surprising, as these patients are known to respond well to immunotherapy. Patients who had gene expression that was angiogenesis-high did better on sunitinib than those with tumors that were angiogenesis-low.
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Long-Term Data Prompt Shifting Approaches to Frontline RCC Therapy
October 8th 2024During a Case-Based Roundtable® event, Chandler Park, MD, moderated a discussion on how recent trial data and sites of metastasis affect treatment of favorable-risk metastatic clear cell renal cell carcinoma in the second article of a 2-part series.
Read More
